We are redefining digestive health by pioneering non-endoscopic diagnostics, enabling early detection of diseases and access to care for everyone, everywhere
Location: United Kingdom
Total raised: $44M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.09.2025 | Series B | $44M | EQT |
Mentions in press and media 4
| Date | Title | Description |
| 02.09.2025 | EQT Life Sciences Leads USD 44 Million Series B Financing in Cyted Health to Accelerate US Expansion | EQT Life Sciences Leads USD 44 Million Series B Financing in Cyted Health to Accelerate US Expansion Tue, Sep 02, 2025 11:00 CET Report this content Amsterdam, The Netherlands, September 2, 2025 – EQT Life Sciences is pleased to announce th... |
| 02.09.2025 | Cyted Health Raises USD44M in Series B Funding | Cyted Health, a Cambridge, UK-based gastrointestinal (GI) molecular diagnostics company, raised USD44M in Series B funding. The round was led by EQT Life Sciences. The company intends to use the funds to accelerate the commercial expansion ... |
| 02.09.2025 | Diagnostics startup Cyted Health secures $44M Series B | Gastrointestinal diagnostics startup Cyted Health has secured $44 million in Series B funding, led by EQT Life Sciences, with Advent Life Sciences and the British Business Bank (formerly British Patient Capital) joining as co-leads. Existin... |
| 01.09.2025 | Cambrige’s Cyted Health raises over €37 million to improve early detection and prevention of oesophageal cancer | Cyted Health, a British gastrointestinal (GI) molecular diagnostics company, announced this weekend a first close of €37.5 million in its Series B financing round to accelerate its ongoing US expansion. The round was led by EQT Life Science... |